{"disease":{"id":"epidermolysis-bullosa","name":"Epidermolysis bullosa","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"birch-bark-extract","indication_name":"Epidermolysis bullosa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Filsuvez","generic_name":"birch bark extract","company_name":"Amryt Pharmaceuticals Dac","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":"Filsuvez works by targeting the underlying cause of Epidermolysis bullosa to reduce skin blistering."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe epidermolysis bullosa acquisita","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe epidermolysis bullosa acquisita in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"filsuvez","indication_name":"Epidermolysis bullosa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Filsuvez","company_name":"Amryt Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"garadacimab","indication_name":"Epidermolysis bullosa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Filsuvez","generic_name":"garadacimab","company_name":"CSL Behring","drug_phase":"marketed","molecular_target":"Activated Factor XII (FXIIa)","drug_class":"Anti-Factor XIIa monoclonal antibody","quality_score":null,"revenue":null,"mechanism":"Monoclonal antibody that inhibits activated Factor XII (FXIIa), preventing the generation of bradykinin which causes angioedema attacks."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT05954416","title":"FARD (RaDiCo Cohort) (RaDiCo-FARD)","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT06330324","title":"Reproductive Options in Inherited Skin Diseases","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":650,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06423573","title":"A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez","phase":"","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"Amryt Pharma","has_results":false},{"nct_id":"NCT03068780","title":"Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Amryt Research Limited","has_results":true},{"nct_id":"NCT02384460","title":"ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Scioderm, Inc.","has_results":true},{"nct_id":"NCT02670330","title":"Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":152,"lead_sponsor_name":"Scioderm, Inc.","has_results":true},{"nct_id":"NCT03158662","title":"Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Amicus Therapeutics","has_results":false},{"nct_id":"NCT07482813","title":"An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Paradigm Therapeutics","has_results":false},{"nct_id":"NCT07482787","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Paradigm Therapeutics","has_results":false},{"nct_id":"NCT01019148","title":"Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03269474","title":"Computational Drug Repurposing for All EBS Cases","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Joyce Teng","has_results":false},{"nct_id":"NCT03154333","title":"Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Castle Creek Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT03389308","title":"Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Castle Creek Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT04917887","title":"Long-Term Follow-up Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT05390073","title":"Growth Hormone in EB","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT05033574","title":"The State of Sexual Development in Children With Inherited Epidermolysis Bullosa","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"National Medical Research Center for Children's Health, Russian Federation","has_results":false},{"nct_id":"NCT02014376","title":"Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Scioderm, Inc.","has_results":true},{"nct_id":"NCT04917874","title":"A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT02090283","title":"Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"Scioderm, Inc.","has_results":true},{"nct_id":"NCT04217538","title":"Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05378997","title":"Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Xinnate AB","has_results":false},{"nct_id":"NCT02670837","title":"Study of Cellutome System for Treatment of Individual Lesions in EB Pts","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT06594393","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Xinnate AB","has_results":false},{"nct_id":"NCT04491604","title":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":true},{"nct_id":"NCT06177353","title":"Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02178969","title":"Short Term Observational Study in DEB Patients","phase":"","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT03836001","title":"A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04757727","title":"Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)","phase":"","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06330350","title":"Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT07230223","title":"Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Isfahan University of Medical Sciences","has_results":false},{"nct_id":"NCT06509984","title":"A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05843994","title":"Artificial Intelligence Patient App for RDEB SCCs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04727268","title":"Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"University Hospital Birmingham NHS Foundation Trust","has_results":false},{"nct_id":"NCT04908215","title":"INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"InMed Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03529877","title":"Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"RHEACELL GmbH & Co. KG","has_results":false},{"nct_id":"NCT05533866","title":"Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03241628","title":"Proof of Concept Study for a Dressing Glove","phase":"","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT02654483","title":"Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Jean Yuh Tang","has_results":true},{"nct_id":"NCT05725018","title":"A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":false},{"nct_id":"NCT01263379","title":"Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":true},{"nct_id":"NCT03536143","title":"A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":true},{"nct_id":"NCT03752905","title":"A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Phoenix Tissue Repair, Inc.","has_results":false},{"nct_id":"NCT02793960","title":"Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Shasa Hu","has_results":false},{"nct_id":"NCT03472287","title":"To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Castle Creek Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT04227106","title":"Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":false},{"nct_id":"NCT06136403","title":"A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03730584","title":"Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04853667","title":"Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05651607","title":"Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}